These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16330270)

  • 1. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population.
    Huybrechts KF; Ishak KJ; Caro JJ
    Bone; 2006 Jun; 38(6):922-8. PubMed ID: 16330270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance with drug therapies for the treatment and prevention of osteoporosis.
    McCombs JS; Thiebaud P; McLaughlin-Miley C; Shi J
    Maturitas; 2004 Jul; 48(3):271-87. PubMed ID: 15207894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study.
    Ward A; Ishak K; Proskorovsky I; Caro J
    Clin Ther; 2006 Nov; 28(11):1912-21. PubMed ID: 17213012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population.
    Bhosle MJ; Reardon G; Camacho FT; Anderson RT; Balkrishnan R
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):100-11. PubMed ID: 17719512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of bisphosphonate therapy in a community setting.
    Feldstein AC; Weycker D; Nichols GA; Oster G; Rosales G; Boardman DL; Perrin N
    Bone; 2009 Jan; 44(1):153-9. PubMed ID: 18926939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data.
    Stern L; Berman J; Lumry W; Katz L; Wang L; Rosenblatt L; Doyle JJ
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):402-8. PubMed ID: 17042149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and consequences of noncompliance to oral bisphosphonate treatment.
    Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
    J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of poor compliance with bisphosphonates.
    Briesacher BA; Andrade SE; Yood RA; Kahler KH
    Bone; 2007 Nov; 41(5):882-7. PubMed ID: 17707710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
    Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
    Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.
    Cole JA; Norman H; Weatherby LB; Walker AM
    Pharmacotherapy; 2006 Aug; 26(8):1157-64. PubMed ID: 16863491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.